Do analysts prefer DMAC or RLYB?

DiaMedica Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 85.47%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DiaMedica Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend RLYB or XFOR?

X4 Pharmaceuticals has a consensus price target of $11.25, indicating a potential upside of 221.43%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 X4 Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to RLYB or XFOR?

In the previous week, X4 Pharmaceuticals had 10 more articles in the media than Rallybio. MarketBeat recorded 13 mentions for X4 Pharmaceuticals and 3 mentions for Rallybio. Rallybio's average media sentiment score of 1.20 beat X4 Pharmaceuticals' score of 0.35 indicating that Rallybio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive X4 Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RLYB or QTTB?

Q32 Bio has a consensus target price of $31.00, indicating a potential upside of 179.28%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts clearly believe Q32 Bio is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Q32 Bio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has preferable earnings & valuation, RLYB or QTTB?

Q32 Bio has higher revenue and earnings than Rallybio. Rallybio is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rallybio $860K 104.22 -$8.98M -$4.34 N/A Q32 Bio $53.74M 6.15 $29.82M $3.00 3.70

Is RLYB or QTTB more profitable?

Q32 Bio has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Q32 Bio's return on equity of 50.17% beat Rallybio's return on equity. Company Net Margins Return on Equity Return on Assets Rallybio -911.07% -40.53% -38.13% Q32 Bio N/A 50.17% 29.49%

Does the media refer more to RLYB or QTTB?

In the previous week, Q32 Bio had 3 more articles in the media than Rallybio. MarketBeat recorded 6 mentions for Q32 Bio and 3 mentions for Rallybio. Rallybio's average media sentiment score of 1.20 beat Q32 Bio's score of 1.19 indicating that Rallybio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RLYB or SION?

Sionna Therapeutics has a consensus price target of $42.22, indicating a potential upside of 437.86%. Given Sionna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sionna Therapeutics is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sionna Therapeutics 1 Sell rating(s) 11 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to RLYB or SION?

In the previous week, Sionna Therapeutics had 1 more articles in the media than Rallybio. MarketBeat recorded 4 mentions for Sionna Therapeutics and 3 mentions for Rallybio. Rallybio's average media sentiment score of 1.20 beat Sionna Therapeutics' score of 0.63 indicating that Rallybio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RLYB or ABEO?

Abeona Therapeutics has a consensus price target of $19.33, suggesting a potential upside of 257.36%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abeona Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media refer more to RLYB or ABEO?

In the previous week, Abeona Therapeutics had 3 more articles in the media than Rallybio. MarketBeat recorded 6 mentions for Abeona Therapeutics and 3 mentions for Rallybio. Rallybio's average media sentiment score of 1.20 beat Abeona Therapeutics' score of 0.57 indicating that Rallybio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rallybio (RLYB) Competitors

$16.88 +0.13 (+0.78%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$16.91 +0.03 (+0.17%)

As of 09/11/2026 07:30 PM Eastern

Compare

RLYB vs. DMAC, XFOR, QTTB, SION, and ABEO

Should you buy Rallybio stock or one of its competitors? Rallybio's main competitors and comparable companies include DiaMedica Therapeutics (DMAC), X4 Pharmaceuticals (XFOR), Q32 Bio (QTTB), Sionna Therapeutics (SION), and Abeona Therapeutics (ABEO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rallybio compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Rallybio (NASDAQ:RLYB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

DiaMedica Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 85.47%. Given DiaMedica Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by insiders. Comparatively, 10.3% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

DiaMedica Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.85, meaning that its share price is 185% less volatile than the broader market.

DiaMedica Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -40.53% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Rallybio	-911.07%	-40.53%	-38.13%

In the previous week, Rallybio had 2 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Rallybio and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.87 beat Rallybio's score of 1.20 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
DiaMedica Therapeutics	Very Positive
Rallybio	Positive

Rallybio has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Rallybio	$860K	104.22	-$8.98M	-$4.34	N/A

Summary

Rallybio beats DiaMedica Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rallybio compare to X4 Pharmaceuticals?

Rallybio (NASDAQ:RLYB) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, X4 Pharmaceuticals had 10 more articles in the media than Rallybio. MarketBeat recorded 13 mentions for X4 Pharmaceuticals and 3 mentions for Rallybio. Rallybio's average media sentiment score of 1.20 beat X4 Pharmaceuticals' score of 0.35 indicating that Rallybio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

X4 Pharmaceuticals has a net margin of -568.80% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -40.53% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-40.53%	-38.13%
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%

Rallybio has higher earnings, but lower revenue than X4 Pharmaceuticals. Rallybio is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	104.22	-$8.98M	-$4.34	N/A
X4 Pharmaceuticals	$35.11M	9.88	-$79.20M	-$1.20	N/A

Rallybio has a beta of -0.85, meaning that its share price is 185% less volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

X4 Pharmaceuticals has a consensus price target of $11.25, indicating a potential upside of 221.43%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 10.3% of Rallybio shares are owned by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

X4 Pharmaceuticals beats Rallybio on 10 of the 16 factors compared between the two stocks.

How does Rallybio compare to Q32 Bio?

Rallybio (NASDAQ:RLYB) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Q32 Bio has a consensus target price of $31.00, indicating a potential upside of 179.28%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts clearly believe Q32 Bio is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Q32 Bio had 3 more articles in the media than Rallybio. MarketBeat recorded 6 mentions for Q32 Bio and 3 mentions for Rallybio. Rallybio's average media sentiment score of 1.20 beat Q32 Bio's score of 1.19 indicating that Rallybio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Q32 Bio has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Q32 Bio's return on equity of 50.17% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-40.53%	-38.13%
Q32 Bio	N/A	50.17%	29.49%

Rallybio has a beta of -0.85, meaning that its stock price is 185% less volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

Q32 Bio has higher revenue and earnings than Rallybio. Rallybio is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	104.22	-$8.98M	-$4.34	N/A
Q32 Bio	$53.74M	6.15	$29.82M	$3.00	3.70

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 10.3% of Rallybio shares are owned by company insiders. Comparatively, 34.5% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Q32 Bio beats Rallybio on 14 of the 17 factors compared between the two stocks.

How does Rallybio compare to Sionna Therapeutics?

Rallybio (NASDAQ:RLYB) and Sionna Therapeutics (NASDAQ:SION) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

90.3% of Rallybio shares are owned by institutional investors. 10.3% of Rallybio shares are owned by company insiders. Comparatively, 5.1% of Sionna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Rallybio has a beta of -0.85, indicating that its stock price is 185% less volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Rallybio has higher revenue and earnings than Sionna Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	104.22	-$8.98M	-$4.34	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A

In the previous week, Sionna Therapeutics had 1 more articles in the media than Rallybio. MarketBeat recorded 4 mentions for Sionna Therapeutics and 3 mentions for Rallybio. Rallybio's average media sentiment score of 1.20 beat Sionna Therapeutics' score of 0.63 indicating that Rallybio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sionna Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Sionna Therapeutics' return on equity of -32.94% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-40.53%	-38.13%
Sionna Therapeutics	N/A	-32.94%	-31.08%

Sionna Therapeutics has a consensus price target of $42.22, indicating a potential upside of 437.86%. Given Sionna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sionna Therapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Sionna Therapeutics beats Rallybio on 10 of the 15 factors compared between the two stocks.

How does Rallybio compare to Abeona Therapeutics?

Rallybio (NASDAQ:RLYB) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Abeona Therapeutics has a consensus price target of $19.33, suggesting a potential upside of 257.36%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Abeona Therapeutics had 3 more articles in the media than Rallybio. MarketBeat recorded 6 mentions for Abeona Therapeutics and 3 mentions for Rallybio. Rallybio's average media sentiment score of 1.20 beat Abeona Therapeutics' score of 0.57 indicating that Rallybio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abeona Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 10.3% of Rallybio shares are owned by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Rallybio has a beta of -0.85, indicating that its stock price is 185% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

Abeona Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -40.53% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-40.53%	-38.13%
Abeona Therapeutics	N/A	-41.69%	-30.36%

Abeona Therapeutics has higher revenue and earnings than Rallybio. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	104.22	-$8.98M	-$4.34	N/A
Abeona Therapeutics	$5.82M	53.15	$71.18M	-$1.09	N/A

Summary

Abeona Therapeutics beats Rallybio on 10 of the 16 factors compared between the two stocks.

Get Rallybio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLYB vs. The Competition

Export

Metric	Rallybio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$89.61M	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	-3.89	14.18	274.94	25.36
Price / Sales	104.22	1,374.99	686.57	116.78
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	1.54	15.12	10.33	6.20
Net Income	-$8.98M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-0.24%	-4.34%	-3.32%	-2.35%
1 Month Performance	-0.47%	0.54%	-0.53%	-3.23%
1 Year Performance	251.20%	40.74%	23.51%	8.79%

Rallybio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLYB Rallybio	0.5164 of 5 stars	$16.88 +0.8%	N/A	+251.2%	$89.61M	$860K	N/A	40	News Coverage Positive News Analyst Downgrade
DMAC DiaMedica Therapeutics	1.8736 of 5 stars	$6.62 +1.2%	$12.00 +81.2%	-8.7%	$357.02M	N/A	N/A	20	Positive News
XFOR X4 Pharmaceuticals	1.618 of 5 stars	$3.51 -0.1%	$11.25 +221.0%	+7.4%	$349.50M	$35.11M	N/A	80	Trending News Analyst Revision
QTTB Q32 Bio	3.9737 of 5 stars	$11.50 -1.6%	$31.00 +169.5%	+475.1%	$343.09M	$53.74M	3.84	39	Positive News
SION Sionna Therapeutics	2.6271 of 5 stars	$7.39 +1.2%	$42.22 +471.7%	-65.6%	$333.88M	N/A	N/A	35	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLYB) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rallybio (RLYB) Competitors

RLYB vs. DMAC, XFOR, QTTB, SION, and ABEO

How does Rallybio compare to DiaMedica Therapeutics?

Summary

How does Rallybio compare to X4 Pharmaceuticals?

Summary

How does Rallybio compare to Q32 Bio?

Summary

How does Rallybio compare to Sionna Therapeutics?

Summary

How does Rallybio compare to Abeona Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB vs. The Competition

Rallybio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rallybio (RLYB) Competitors

RLYB vs. DMAC, XFOR, QTTB, SION, and ABEO

How does Rallybio compare to DiaMedica Therapeutics?

Do analysts prefer DMAC or RLYB?

Do insiders and institutionals believe in DMAC or RLYB?

Which has more risk and volatility, DMAC or RLYB?

Is DMAC or RLYB more profitable?

Does the media favor DMAC or RLYB?

Which has stronger earnings & valuation, DMAC or RLYB?

Summary

How does Rallybio compare to X4 Pharmaceuticals?

Does the media refer more to RLYB or XFOR?

Is RLYB or XFOR more profitable?

Which has higher valuation and earnings, RLYB or XFOR?

Which has more volatility & risk, RLYB or XFOR?

Do analysts recommend RLYB or XFOR?

Do institutionals & insiders believe in RLYB or XFOR?

Summary

How does Rallybio compare to Q32 Bio?

Do analysts recommend RLYB or QTTB?

Does the media refer more to RLYB or QTTB?

Is RLYB or QTTB more profitable?

Which has more risk and volatility, RLYB or QTTB?

Which has preferable earnings & valuation, RLYB or QTTB?

Do institutionals and insiders believe in RLYB or QTTB?

Summary

How does Rallybio compare to Sionna Therapeutics?

Do institutionals and insiders have more ownership in RLYB or SION?

Which has more risk & volatility, RLYB or SION?

Which has better valuation and earnings, RLYB or SION?

Does the media refer more to RLYB or SION?

Is RLYB or SION more profitable?

Do analysts rate RLYB or SION?

Summary

How does Rallybio compare to Abeona Therapeutics?

Do analysts rate RLYB or ABEO?

Does the media refer more to RLYB or ABEO?

Do institutionals & insiders hold more shares of RLYB or ABEO?

Which has more risk and volatility, RLYB or ABEO?

Is RLYB or ABEO more profitable?

Which has stronger earnings & valuation, RLYB or ABEO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB vs. The Competition

Rallybio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools